Dalby Earns CPRIT Grant for Drug Delivery Program

A person wearing a mask in a lab.
September 16, 2021
The Cancer Prevention and Research Institute of Texas (CPRIT) recently awarded grants to six faculty members at UT Austin, including the Division of Chemical Biology and Medicinal Chemistry's Kevin Dalby, Ph.D. for his Targeted Therapeutic Drug Discovery and Development Program.

Texas Pharmacy Rises to #8 Nationally for Total Research Funding

#8 Total Research Funding Rank for UT Pharmacy.
June 15, 2021
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.

TxCORE Research Wins PhRMA Foundation Award

Three people smiling.
April 1, 2021
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.

H-E-B Opens New Pharmacy on UT Austin Campus

Two men holding mugs and talking.
October 21, 2020
“H-E-B has been an innovator in community pharmacy practice in Texas. The UT College of Pharmacy has a long history of collaboration with H-E-B, including training the next generation of pharmacists through internships, experiential rotations, and post-graduate residencies,” said Dean Samuel M. Poloyac. “The opening of the new pharmacy on the UT Austin campus is a wonderful opportunity to enhance our partnership. We are excited to work together on this new endeavor.”

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.